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Background: Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of
immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 and
cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade, clinical response to either of these single agents has been
limited to 11-20% of treated patients. Therefore, in this study, we sought to test the hypothesis that the combination of
IL-2 and CTLA-4 blockade could mediate a more profound therapeutic response.
Methods: Here, B6 mice were challenged with poorly immunogenic B16 melanoma on day 0, and treated with CTLA-4
blocking antibody (100 μg/mouse) on days 3, 6, and 9, and IL-2 (100,000 units) twice daily on days 4–8, or both.
Results: A highly significant synergistic effect that delayed tumor growth and prolonged survival was demonstrated
with the combination immunotherapy compared to either monotherapy alone. The therapeutic effect of combination
immunotherapy was dependent on both CD8+ T and NK cells and co-depletion of these subsets (but not either one
alone) abrogated the therapeutic effect. CTLA-4 blockade increased immune cell infiltration (including CD8+ T cells and
NK cells) in the tumor and IL-2 reduced the proportion of highly differentiated/exhausted tumor-infiltrating NK cells.
Conclusions: These results have implications for the design of clinical trials in patients with metastatic melanoma and
provide new insights into how the immune system may be mediating anti-tumor activity with combination IL-2 and
CTLA-4 blockade in melanoma.
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Melanoma is a tumor of melanocytes and is one of the
few types of cancer with an increasing annual incidence
[1,2]. Significant advances have been made in treating
melanoma using targeted therapy and tumor immuno-
therapy. Targeted therapy is based on directly inhibiting
specific intracellular driver mutations that mediate tumor
cell proliferation, and randomized clinical trials have* Correspondence: howard.kaufman@rutgers.edu
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unless otherwise credited.demonstrated improvements in overall survival for pa-
tients treated with inhibitors of mutated BRAF and MEK,
members of the Ras-Raf-MEK-ERK mitogen-activated
protein kinase signaling pathway [3-5]. The benefits in
survival are complicated by a nearly universal emergence
of drug resistance and tumor recurrence [6]. In contrast
to targeted therapy, immunotherapy mediates anti-tumor
activity indirectly by activating tumor-specific effector
lymphocytes [7,8]. In murine models of tumor immuno-
surveillance, complete elimination of spontaneously aris-
ing tumors is possible but depends on several factors,
including interferon-gamma, Fas/FasL interactions, per-
forin, NKG2D, and an intact lymphocyte compartment
[9]. Tumor immunotherapy mediates anti-tumor activityral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CD8+ T cells. Immunotherapy has been associated with
significant clinical benefit characterized by durable re-
sponses in subsets of patients even in the presence of
advanced metastatic disease [10,11]. Several agents, in-
cluding interferon-alpha, high-dose interleukin-2 (IL-2),
and checkpoint inhibitors targeting the cytotoxic T
lymphocyte antigen 4 (CTLA-4) and programmed cell
death 1 (PD-1) receptors have been approved by the
FDA for the treatment of metastatic melanoma [12].
IL-2 is a four-bundle, alpha-helical cytokine released
by lymphocytes that binds to the high-affinity trimeric
IL-2 receptor expressed on activated lymphocytes and
natural killer (NK) cells. IL-2 mediates proliferation and
differentiation of T, B, and NK cells and promotes clonal
expansion following T cell receptor (TCR) recognition of
cognate antigen [13]. IL-2 has been associated with ob-
jective response rates of 16-20% in patients with meta-
static melanoma and responders have durable tumor
control with nearly 90% of complete responders free of
disease recurrence up to 15 years following treatment
[14]. High-dose IL-2 presumably mediates anti-tumor
activity through expansion of the CD8+ T cell and NK
cell compartments, but it is also known to expand regu-
latory CD4+ FoxP3+ T cells (Tregs), which can mediate
immune suppression and promote peripheral tolerance
[15,16]. In fact, low doses of IL-2 have been used to pro-
tect against graft-versus-host disease and may abrogate
autoimmunity [17,18]. Melanoma patients treated with
high-dose IL-2 have shown an expansion of the Treg
compartments; however, those patients with a clinical
response exhibit a paradoxical decrease in Tregs follow-
ing treatment [19]. Although the mechanism of this
decrease is not understood, blocking the expansion of
Tregs could improve tumor immunotherapy with IL-2
by taking advantage of the expansion of CD8+ effector T
and NK cells [20].
CTLA-4 is an immunoglobulin-like family co-receptor
that is mobilized to the T cell surface following TCR
engagement and co-stimulation [21]. Full activation of T
cells requires two signals, the first mediated by the TCR
upon recognition of antigen in the form of peptide
bound to MHC class I and II molecules for CD8+
and CD4+ T cells, respectively. CD28 is a master co-
stimulatory receptor that is expressed near the TCR
and can be stimulated by B7.1 (CD80) and B7.2
(CD86), usually expressed by antigen-presenting cells
during T cell priming [22]. CD28 signals intracellularly
and coordinates cell proliferation, cytokine production,
differentiation and blocks lymphocyte apoptosis [23]. Fol-
lowing co-stimulation, CTLA-4 is mobilized to the cell
surface where it binds with higher affinity to CD80 and
CD86, thereby inhibiting lymphocyte effector functions.
CTLA-4 thus acts as a T cell checkpoint inhibitor, blockinguncontrolled effector cell activity and likely functions to
prevent autoimmunity. Ipilimumab is an IgG1 monoclonal
antibody that blocks the interaction of CTLA-4 with its
ligand and promotes the activation of T cells [24]. The FDA
approved ipilimumab for the treatment of melanoma in
2011 after a randomized clinical trial showed an improve-
ment in overall survival in patients with metastatic melan-
oma [25]. The objective response rate with ipilimumab was
reported to be 10.9%, although when responses occurred
they were often quite durable [25,26].
In general, clinical response to single agent therapy
(monotherapy) has been limited to a small group of pa-
tients, generally in the range of 11-24% [26]. While these
agents have shown significant therapeutic activity against
a variety of murine tumors, they have demonstrated only
limited therapeutic activity against the poorly immuno-
genic murine B16 melanoma [27-31]. Thus, the B16
model may represent a relevant system for evaluating
new treatment approaches and can be used to identify
the cellular and molecular mechanisms that result in
more meaningful therapeutic activity. The possibility of
combining immunotherapy agents has suggested that
additive and even synergistic activity may be observed in
both murine tumor models and in early phase clinical
trials [31,32,2]. In this report, we sought to test the
hypothesis that combination of high-dose IL-2 and
CTLA-4 blockade could mediate more profound thera-
peutic activity using the B16 melanoma tumor model. A
highly significant synergistic effect on survival was dem-
onstrated, without added toxicity, and this effect was
dependent on both CD8+ T and NK cells. These results
have implications for the design of clinical trials in
patients with metastatic melanoma and provide new in-
sights into how the immune system may be mediating
anti-tumor activity with combination IL-2 and CTLA-4
blockade.
Results and Discussion
Combination immunotherapy with IL-2 and CTLA-4 blockade
results in significantly delayed tumor growth and prolonged
survival
IL-2 therapy and CTLA-4 blockade have individually
been shown to improve anti-tumor responses and are
approved as monotherapies for the treatment of meta-
static melanoma [12,14,25]. Since each of these mono-
therapies may work through a unique mechanism, we
explored the effect of combination IL-2 and CTLA-4
blockade immunotherapy using the murine B16-F10
(B16) melanoma model. Specifically, we challenged mice
with B16 (1–1.2 x 105 cells by intradermal injection) and
treated with CTLA-4 blockade (αCTLA-4; 100 μg via
intraperitoneal injection [i.p.] on days 3, 6 and 9 after
tumor challenge) only, IL-2 (100,000 units i.p every
12 hours on days 4–8 post tumor challenge) only, or the
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the treatment regimen to correspond with the manner
in which these monotherapies are utilized in the clinical
setting (Figure 1A). We found that both monotherapies,
IL-2 and CTLA-4 blockade individually delayed tumor
growth compared to the control (IgG + PBS) treatment
(29 mm2 and 14 mm2 versus 76 mm2; p < 0.01 and
p < 0.001, respectively, at day 14) (Figure 1B, C) and
prolonged survival (30% and 50% versus 0%; p < 0.05
and p < 0.001, respectively, at day 23) (Figure 1D).Figure 1 Combination IL-2 and CTLA-4 blockade immunotherapy results in
experimental design. (B) Cumulative graph of mean tumor size (mm2) per
individual mice in each group from experiment described in (A). (D) Cumu
described in (A). Seven to ten mice were included in each group. Graphs r
*P < 0.05, **P < 0.001, ***P < 0.001, ns = not significant.Combination IL-2 and CTLA-4 blockade resulted in
significantly delayed tumor growth compared to IL-2
only or CTLA-4 blockade only (2 mm2 versus 29 mm2
[p < 0.01] and 14 mm2 [p < 0.01], respectively, at day 14)
and significantly prolonged survival (100% versus 30%
[p < 0.01] and 50% [p < 0.05], respectively, at day 23)
(Figure 1B-D). No added toxicity was detected with
combination IL-2 and CTLA-4 blockade compared to
either treatment alone (Table 1). These findings demon-
strate an augmented anti-tumor effect with combinationreduced tumor growth and prolonged survival. (A) Schematic of the
group from experiment described in (A). (C) Tumor size (mm2) of
lative graph of mean percent (%) survival per group from experiment
epresent one experiment of six conducted with similar results.
Table 1 Chemistry screen IL-2 and of CTLA-4 blockade immunotherapy
Treatment Naive IL-2 CTLA-4 blockade CTLA-4 blockade + IL-2 Reference ranges
Alkaline Phosphatase (U/L) 49 12 56 50 34 - 104
ALT (U/L) 40 198 26 63 8 - 40
AST (U/L) 160 238 134 123 10 - 45
Total Bilirubin (mg/dL) 0.35 0.72 0.44 0.30 0.20 - 0.10
BUN (mg/dL) 28 34 36 35 6 - 23
Creatinine (mg/dL) 0.17 0.05 0.12 0.2 0.50 - 1.30
Calcium (mg/dL) 8.13 6.14 7.86 11.58 8.40 - 10.50
Glucose (mg/dL) 58 32 18 27 75 - 200
Albumin (g/dL) 3.95 3.79 4.13 3.91 3.50 - 5.70
Total Protein (g/dL) 7.17 6.62 7.01 6.80 6.00 - 8.40
Phosphorus (mg/dL) 38.1 33 34.6 35.5 2.4 - 4.5
ALT, Alanine Transaminase; AST, Aspartate Aminotransferase; BUN, Blood Urea Nitrogen.
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either monotherapy alone against established, poorly im-
munogenic melanoma.
CTLA-4 blockade promotes immune cell infiltration within
the tumor
Immune infiltration within the tumor is a positive prog-
nostic indicator of response to immunotherapy [33,34].
Thus, we assessed immune infiltration of B16 by deter-
mining the proportion of CD45+ cells within the tumor
following treatment. To distinguish between tumor-
resident immune infiltration and immune cells restricted
to the vasculature, we intravenously injected anti-CD45
conjugated to a fluorophore three minutes prior to sacri-
ficing the mice. Following tumor dissection and tissue
dissociation, we stained cells in vitro with anti-CD45
conjugated to a different fluorophore than the one used
for intravenous in vivo staining. This permitted the iden-
tification of tumor-resident leukocytes by flow cytometry
(Figure 2A). CTLA-4 blockade alone and in combination
with IL-2 promoted CD45+ immune infiltration (among
live cells) compared to the control treatment (mean
%CD45+ cells in the tumor: 48% and 28% versus 11%,
p < 0.001 and p < 0.05, respectively) (Figure 2A,B). No
significant difference in immune infiltration was ob-
served between the combination group and the CTLA-4
blockade treatment group (48% versus 28%, respectively,
p > 0.05) or between IL-2 alone and the control group
(18% versus 11%, respectively, p > 0.05) (Figure 2B). Fur-
ther, to confirm that the combination immunotherapy
enhanced immune infiltration, we used epifluorescence
microscopy. This demonstrated that IL-2 and CTLA-4
blockade combination immunotherapy results in
augmented CD45+ immune cell infiltration within the
tumor (1x105 versus 4x104 CD45+ cells/106 nuclei,
respectively, p < 0.05) (Figure 2C). These data demon-
strate that CTLA-4 blockade, individually and whencombined with IL-2, promotes immune cell infiltration
within the tumor microenvironment.
CTLA-4 blockade results in increased CD8+ T cells in the
tumor microenvironment
CD8+ T cells are vital mediators of anti-tumor
responses. Therefore, we characterized the tumor
immune infiltrate to determine the effect of combination
IL-2 and CTLA-4 blockade on CD8+ T cells. CTLA-4
blockade alone and in combination with IL-2 resulted in
an increased proportion of CD8+ T cells among the im-
mune cell infiltrate (CD45+ cells) of the tumor compared
to the control group (35% and 19% versus 7%, p < 0.01
and p < 0.05, respectively) (Figure 3A,B). No significant
difference in immune infiltration was observed between
the combination group and the CTLA-4 blockade only
treatment group (19% versus 34%, respectively, p > 0.05)
or between IL-2 alone and the control group (6% versus
7%, respectively, p > 0.05) (Figure 3A, B). These data
suggest that CTLA-4 blockade may be the primary driver
of CD8+ T cell tumor infiltration after CTLA-4 blockade
with or without IL-2 immunotherapy.
To determine whether the increased proportion of
CD8+ T cells in the tumor microenvironment was the
result of an overall systemic increase in CD8+ T cells,
we analyzed the tumor-draining (inguinal) lymph nodes
and spleen for CD8+ T cell numbers. No increase was
observed in the proportion of CD8+ T cells within the
tumor-draining lymph nodes as a result of IL-2 alone,
CTLA-4 blockade alone, or combination IL-2 and
CTLA-4 blockade compared to the control treatment
(in all groups CD8+ T cells constituted approximately 27%
of CD45+ cells, p > 0.05 for all comparisons) (Figure 3C).
Similarly, no differences in CD8+ T cells amongst the
groups were seen in the spleen (data not shown). This
demonstrates that the increased proportion of tumor-
infiltrating CD8+ T cells is not the result of a systemic
Figure 2 Combination IL-2 and CTLA-4 blockade immunotherapy increases tumor immune infiltration. (A) Flow cytometry plots of tumors
dissected at day 14 and analyzed by flow cytometry for CD45 expression from the experiment described in Figure 1A. Only tumor-infiltrating
lymphocytes were analyzed (as determined by comparison of intravenous CD45 staining compared to in vitro CD45 staining). (B) Cumulative graph
showing mean percent CD45+ T cell infiltration (of live cells) in the tumor from three independent experiments described in (A). (C) Representative
immunofluorescence microscopy images of CD45 (red) and DAPI (4′,6-diamidino-2-phenylindole; blue) staining of tumors from experiment in
(A). Scale bars = 20 microns. Three to five mice were included in each group per experiment. *P < 0.05, ***P < 0.001, ns = not significant.
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specific to the tumor microenvironment.
To determine whether the activation status of CD8+ T
cells correlates with the anti-tumor immune responses
we observed (Figure 1B,C), we determined the expression
of CD8+ T cell activation markers. Tumor-infiltrating
CD8+ T cells showed an activated phenotype (with in-
creased CD44, CD25, CD69, and Tbet expression and
decreased CD62L expression) compared to CD8+ T
cells in the tumor-draining lymph nodes (Figure 3D).
However, we observed no differences in these activa-
tion markers when comparing the monotherapies (IL-2
or CTLA-4 blockade) or the combination IL-2 and
CTLA-4 blockade immunotherapy to the control
group (IgG + PBS) (Figure 3D). Since PD-1 is known to
be upregulated during T cell activation, we likewise de-
termined its expression on tumor-infiltrating CD8+ T
cells. IL-2 and CTLA-4 blockade monotherapies as
well as the combination IL-2 and CTLA-4 blockade
immunotherapy resulted in an increased proportion of
CD8+ T cells expressing PD-1 (among all CD8+ T cells)
within the tumor (46%, 43%, 53% versus 24%, p < 0.01,
p < 0.05, and p < 0.01, respectively) (Figure 3E). How-
ever, no differences in PD-1 expression between the
combination immunotherapy and the CTLA-4 blockade
and IL-2 monotherapies (53% versus 46% and 43%, p > 0.05
for both, respectively) were detected. These data dem-
onstrate the activation status of CD8+ T cells does notcorrelate with the improved anti-tumor immune re-
sponses we observed for combination IL-2 and CTLA-4
blockade immunotherapy.
Combination CTLA-4 blockade and IL-2 immunotherapy
increases regulatory T cells within the tumor immune
infiltrate
Regulatory T cells (Tregs) promote tumor growth through
the suppression of anti-tumor immune responses. Tregs
suppress CD8+ T cell and NK cell responses specifically
through CTLA-4 [35] and by acting as IL-2 sinks through
expression of high levels of the high affinity IL-2 receptor,
CD25 [36]. Thus, we determined whether combination
IL-2 and CTLA-4 blockade immunotherapy affects Tregs
in the tumor. While CTLA-4 blockade alone and IL-2
alone did not increase the proportion of Tregs (among
CD45 + CD3+ cells) within the tumor compared to the
control treatment (1% and 2% versus 2%, p > 0.05 for both,
respectively), the combination of these immunotherapies
significantly increased Tregs among the immune infiltrate
compared to the control treatment (5% versus 2%, respect-
ively, p < 0.01) (Figure 4A, B). These findings demonstrate
that the improved responses observed with combination
IL-2 and CTLA-4 blockade immunotherapy compared to
either monotherapy are associated, unexpectedly, with an
increase in the proportion of Tregs in the tumor.
The efficacy of immunotherapies has been previously
attributed to their ability to increase the proportion of
Figure 3 Combination IL-2 and CTLA-4 blockade immunotherapy increases the proportion of tumor-infiltrating CD8+ T cells. (A) Flow cytometry
plots of tumors dissected at day 14 and analyzed for CD3 + CD8+ T cells (of CD45+ cells within the tumor) by flow cytometry from the experiment
described in Figure 1A. (B) Cumulative graph showing the mean percent of CD3 + CD8+ T cells from experiment in (A). (C) Cumulative graph showing
the mean percent of CD3 + CD8+ T cells in the tumor-draining lymph nodes from experiment in (A). (D) Representative histograms showing
expression of cell markers from CD3 + CD8+ T cells in the tumor and from a representative tumor-draining lymph node (LN). Numbers
represent mean fluorescence intensity (MFI). (E) Cumulative graph of mean percent of CD3 + CD8+ T cells expressing PD-1 from experiment
in (A). Cumulative figures are from at least three independent experiments (with 3–5 mice per group in each experiment). *P < 0.05, ** P < 0.01,
ns = not significant.
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this ratio within the tumor. We observed a trend to-
wards an increased ratio of CD8+ T cells (of CD45+
cells) to Tregs (of CD45+ cells) in the CTLA-4 blockade
monotherapy group compared to the combination IL-2
and CTLA-4 blockade immunotherapy group (47 versus 8,
respectively, p = 0.06) and compared to the control group
(47 versus 10, respectively, p = 0.07) (Figure 4C). However,
we found no statistically significant differences in the ratio
of CD8+ T cells to Tregs when comparing the combination
IL-2 and CTLA-4 blockade immunotherapy group to any
other group (p > 0.05 for all comparisons) (Figure 4C and
data not shown). These data suggest that the CD8+ T cell
to Treg ratio does not correlate with the improved anti-
tumor responses observed with combination IL-2 andCTLA-4 blockade immunotherapy compared to either
monotherapy in this model.
To determine whether the observed differences and
trends in the proportion of Tregs and the ratio of CD8+
T cells to Tregs was confined to the tumor microenvir-
onment, we determined these measures within the
tumor-draining lymph nodes and spleen. Here, we ob-
served no differences or trends in either the proportion
of Tregs or the ratio of CD8+ T cells to Tregs with the
monotherapies or the combination IL-2 and CTLA-4
blockade in the tumor-draining lymph nodes (in all
groups Tregs constituted 3 to 5% of CD45+ cells, p > 0.05
for all comparisons; and in all groups CD8:Treg ratios
were 6 to 9, p > 0.05 for all comparisons) (Figure 4D, E) or
in the spleen (data not shown). These data suggest that
Figure 4 Combination IL-2 and CTLA-4 blockade immunotherapy increases the proportion of tumor-infiltrating Tregs. (A) Flow cytometry plots of
tumors dissected at day 14 and analyzed for regulatory CD4 + Foxp3+ T cells (Tregs; of CD45 + CD3+ cells within the tumor) by flow cytometry
from the experiment described in Figure 1A. (B) Cumulative graph showing mean percent of Tregs from experiment in (A). (C) Ratio of CD8+ T
cells to Tregs in the tumor from experiment in (A). (D) Cumulative graph showing mean percent of Tregs from the tumor-draining lymph nodes
from experiment in (A). (E) Ratio of CD8+ T cells to Tregs in the tumor-draining lymph node from experiment in (A). Cumulative figures are from
at least three independent experiments (with 3–5 mice per group in each experiment). *P < 0.05, **P < 0.01, ns = not significant.
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Tregs and the ratio of CD8+ T cells to Tregs in the
tumor-draining lymph nodes and spleen do not parallel
those found in the tumor microenvironment.
CTLA-4 blockade increases NK cells within the tumor
infiltrate and IL-2 modulates NK cell differentiation status
Since the therapeutic activity of the combination treat-
ment did not depend on the CD8+ T cell:Treg ratio, we
sought to determine if NK cells were involved in the an-
titumor activity. CTLA-4 blockade alone and in combin-
ation with IL-2 resulted in an increase in the proportion
of NK cells among the non-T cell (CD45 + CD3-) tumor
immune infiltrate compared to the control (32% and
34% versus 15%, p < 0.01 and p < 0.05, respectively)
(Figure 5A,B). There were no differences in NK cellinfiltration between the CTLA-4 blockade only and the
combination IL-2 and CTLA-4 blockade treatment groups
(32% versus 34%, respectively, p > 0.05) (Figure 5A,B). As
with our observation for CD45+ cells, CD8+ T cells, and
Tregs, the increase in the proportion of NK cells was not
observed in the tumor-draining lymph nodes (in all
groups NK cells constituted approximately 2% of CD45+
cells, p > 0.5 for all comparisons) (Figure 5C) or spleen
(data not shown).
To determine whether the activation status of NK cells
correlates with the anti-tumor immune responses we
observed (Figure 1B,C), we determined the expression of
well-described NK cell markers. There were no signifi-
cant differences in tumor-infiltrating NK cell activation
markers PD-1, Tbet, NKG2D, Eomes, and CD127 in the
IL-2 or CTLA-4 blockade monotherapy or combination
Figure 5 Combination IL-2 and CTLA-4 blockade immunotherapy increases the proportion and changes the differentiation of tumor-infiltrating
NK cells. (A) Flow cytometry plots of tumors dissected at day 14 and analyzed for the proportion of NK cells (of CD45 + CD3- cells within the
tumor) by flow cytometry from the experiment described in Figure 1A. (B) Cumulative graph showing mean percent of NK cells from experiment
in (A). (C) Cumulative graph showing mean percent of NK cells from the tumor-draining lymph nodes from experiment in (A). (D) Representative
histograms showing expression of cell markers by NK cells in the tumor and from a representative tumor-draining lymph node (LN). Numbers
represent mean fluorescence intensity (MFI). (E) Flow cytometry plots showing expression of CD27 and CD11b on tumor-infiltrating NK cells from
experiment in (A). Cumulative figures are from at least three independent experiments (with 3–5 mice per group in each experiment). *P < 0.05,
**P < 0.01, ns = not significant.
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group (Figure 5D). Because IL-2 has been reported to
increase the proportion of immature NK cells [37] and
regulate NK cell maturation, as determined by expres-
sion of CD27 and CD11b [38], we determined the effects
of combination IL-2 and CTLA-4 blockade immuno-
therapy on the maturation status of NK cells within the
tumor. Treatment with IL-2 alone and in combination
with CTLA-4 blockade resulted in reduced expression of
CD27 and CD11b compared to the control (3% and 2%
versus 12%, p < 0.05 for both, respectively) on NK cells
suggesting a less differentiated phenotype (Figure 5E).
CTLA-4 blockade had no effect on NK cell maturation
compared to the control group (16% versus 12%, respect-
ively, p > 0.05) (Figure 5E). These results demonstrate that
CTLA-4 blockade and IL-2 work in combination to in-
crease the proportion of NK cells in the tumor infiltrate
(via the effects of CTLA-4 blockade) and to promote a less
differentiated NK cell population (via the effects of IL-2)
within the tumor microenvironment.
Since one possible mechanism through which NK cells
might mediate anti-tumor activity is to delete MHC class
I negative tumor cells, and because melanoma has beenreported to evade immune detection through loss of
MHC class I expression, we evaluated the level of MHC
class I on the B16 tumor cells after in vivo challenge.
We observed that over 92% Melan-A+ cells in the tumor
demonstrated surface expression of MHC class I mol-
ecule H-2Kb (Additional file 1: Figure S1). This finding
suggests that the importance on NK cells in the context
of combination IL-2 and CTLA-4 blockade immuno-
therapy is not based on loss of MHC class I expression
on tumor cells.
CD8+ T cells and NK cells are necessary for the efficacy of
combination IL-2 and CTLA-4 blockade immunotherapy
NK cells can contribute to anti-tumor immune re-
sponses against B16 melanoma, as reported for various
other types of combination immunotherapy approaches
[39-41]. Thus, to determine if NK cells were involved in
the anti-tumor activity of IL-2 and CTLA-4 blockade
treatment, we repeated the tumor studies in Figure 1 in
the absence of NK cell and/or or CD8+ Tcells (Figure 6A).
Individual depletion of CD8+ T cells or NK cells partially
reduced the overall efficacy of the combination immuno-
therapy compared to treatment in immune competent
Figure 6 NK and CD8+ T cells are necessary for combination IL-2 and CTLA-4 blockade immunotherapy-mediated effects. (A) Schematic of the
experimental design. (B) Cumulative graph of the mean tumor size (mm2) per group after CD8 or NK cell depletion (left panel) and B cell or CD4+ cell
depletion (right panel) from the experiment described in (A). (C) Cumulative graph of the mean tumor size (mm2) per group after combination CD8
and NK cell depletion from the experiment described in (A). (D) Tumor size (mm2) of individual mice in each group from experiment described in
(C). Four to ten mice were included in each group. Graphs represent one experiment of three conducted with similar results. *P < 0.05, **P < 0.001,
***P < 0.001, ns = not significant.
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p < 0.001, respectively, at day 12) (Figure 6B, left panel).
However, depletion of either subset individually was
not sufficient to completely ablate therapeutic efficacy
compared to the control (36 mm2 and 22 mm2 versus
69 mm2, p < 0.05 for both, respectively, at day 12)
(Figure 6B, left panel). Depletion of neither CD4 nor B
cells had any effect on the efficacy of the combination
IL-2 and CTLA-4 blockade immunotherapy compared
to no depletion (9 mm2 and 16 mm2 versus 11 mm2,
p > 0.05 for both, respectively, at day 12) (Figure 6B,
right panel). When both CD8+ T cells and NK cells
were depleted concurrently during the course of com-
bination IL-2 and CTLA-4 blockade immunotherapy,
therapeutic responses were abrogated compared to no
depletion (82 mm2 versus 14 mm2, respectively, p < 0.05,
at day 16) and tumor growth resembled that of the control
group when both CD8+ T cells and NK cells were de-
pleted concurrently (82 mm2 versus 55 mm2, respectively,
p > 0.05, at day 16) (Figure 6C,D). Further depletion of
both CD8 T cells and NK cells concurrently reduced the
therapeutic response significantly compared to either
CD8 or NK cell depletion alone (p < 0.01 for bothcomparisons). This demonstrates that both CD8+ T
cells and NK cells are necessary for the therapeutic ef-
fectiveness of combination IL-2 and CTLA-4 blockade
immunotherapy.
Conclusions
High dose IL-2 and CTLA-4 blockade have demon-
strated clinical success in the treatment of advanced
melanoma although the exact mechanism of their anti-
tumor activity is not completely defined [14,12,25].
CTLA-4 suppresses immune responses by limiting co-
stimulation of T cells through binding of CD80 and
CD86 [42] and reducing T cell receptor signaling [42]. In
contrast, IL-2 promotes effector responses, regulates dif-
ferentiation, and mitigates exhaustion of both CD8+ T
cells and NK cells. Previous studies have shown that
CTLA-4 blockade can mediate therapeutic activity by
enhancing T cell responses as a result of increased en-
dogenous expression of local IL-2 [29,43]. Therefore, we
sought to evaluate the combination of CTLA-4 blockade
and high-dose exogenous, recombinant IL-2 with the
hypothesis that CTLA-4 blockade would prevent im-
mune suppression while administration of IL-2 would
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sponses. This combination immunotherapy did improve
therapeutic responses over either CTLA-4 blockade or
IL-2 monotherapy (Figure 1) against the poorly im-
munogenic B16 melanoma. CD8+ T cells and NK cells
were both necessary for the therapeutic effect of the
combination immunotherapy as witnessed by partial re-
ductions in efficacy when either CD8+ T cells or NK
cells were depleted individually (Figure 6). The potential
for improved clinical outcomes has also been suggested
by a small dose escalation clinical trial that tested the
combination of high-dose IL-2 (720,000 IU/kg) with in-
creasing doses of ipilimumab, a humanized monoclonal
antibody that blocks CTLA-4 (range 0.1 - 3.0 mg/kg) in
patients with advanced melanoma [44]. In this trial an
initial objective response rate of 22% was reported. In
further follow-up, however, the overall response rate
improved to 28% with a remarkable 17% of patients
achieving a complete response [45]. This is impressive
considering the delayed responses often observed with
ipilimumab and the fact that some patients received very
low doses of ipilimumab. Our data reported here adds
additional support to further clinical studies of combin-
ation IL-2 and ipilimumab in patients with metastatic
melanoma.
In this study, we found that CTLA-4 blockade pro-
motes immune infiltration into the tumor microenviron-
ment. In particular, CTLA-4 blockade increased the
relative proportion of CD8+ T cells and NK cells among
tumor-infiltrating immune cells. In line with previous
publications that have used CTLA-4 blockade as a
monotherapy [31], we observed that this preferential
infiltration of CD8+ T cells and NK cells resulted in a
trend towards an increased ratio of CD8+ T cells to
Tregs (Figure 4C). This ratio has been suggested as an
indicator of therapeutic response given the anti-tumor
cytotoxicity function of CD8+ T cells as opposed to the
suppressive actions of Tregs [31]. In our model this ratio
was not highly significant and was not increased when
CTLA-4 blockade was combined with IL-2. This may be
related to how the ratio was calculated as we standard-
ized the number of T cells to the CD45+ cell population,
whereas others have standardized to all live cells. Fur-
ther, there is evidence that some Foxp3+ CD4+ T cells
(particularly those that are FoxP3lo) may not be suppres-
sive; therefore, the differences in Foxp3+ CD4+ T cells
may not indicate an increase in suppressive regulatory
CD4+ T cells [46]. Future studies will explore the
suppressive ability of these CD4+ Foxp3+ T cells in the
context of the combination immunotherapy. Another
explanation may be that other mechanisms may mediate
tumor rejection in our model, including the accumula-
tion of less differentiated/exhausted NK cells, which
were increased in the tumor microenvironment of micetreated with the combination immunotherapy. Since IL-
2 is known to expand Tregs it may not be surprising that
therapeutic effects were not associated with a shift in the
CD8:Treg ratio with this therapeutic combination. Stud-
ies of immunosurveillance in mice have suggested that
complete tumor elimination is dependent on induction
of both innate and adaptive immune responses. Thus,
IL-2-mediated expansion of NK cells, which was neces-
sary for the therapeutic activity observed with combin-
ation treatment, may override or supplement a decrease
in Tregs. The necessity of NK cells for therapeutic activ-
ity is in line with other studies highlighting a contribut-
ing role of NK cells in immunotherapy, potentially
through direct cytoxicity or IFN-γ production [41,40,39].
Our results are in agreement with these studies and sup-
ports the potential role of NK cells in immunotherapy
especially in weakly immunogenic tumors.
Although other mechanisms may contribute to the
therapeutic responses, our data suggests that CTLA-4
blockade may help recruit NK cells to the tumor micro-
environment while IL-2 (alone and in combination with
CTLA-4 blockade) altered the maturation of tumor-
infiltrating NK cells. NK cells are thought to progress
through maturation marked by expression of CD27 and
CD11b. NK cells mature first by upregulating CD27 then
CD11b [38]. IL-2 either as a monotherapy or in combin-
ation with CTLA-4 blockade increased the proportion of
less fully differentiated (CD27-CD11b-) NK cells as com-
pared with the exhausted (CD11b+) NK cells within the
tumor observed with CTLA-4 blockade alone. These re-
sults, when considered with the data demonstrating that
NK cells participate in mediating the therapeutic efficacy
of the combination immunotherapy, suggest that IL-2
has a role in the NK cell portion of this response, poten-
tially through reducing NK cell exhaustion or expanding
non-exhausted NK cells. NK cells may also cooperate
with CD8+ T cells by targeting MHC class I-negative
and -positive tumor cells, respectively. This is unlikely
the case in this model as MHC class I expression was
quite robust following in vivo tumor transplantation.
Since NKG2D has been shown to help mediate tumor
elimination during immunosurveillance of spontaneous
tumors, it is also possible that less differentiated NK
cells recruited to the microenvironment may utilize
NKG2D to help mediate tumor immunotherapy. Since
NK cell recruitment may also result in release of local
interferon-gamma, this might also help improve CD8+ T
cell function by up-regulating tumor antigens, MHC
Class I and enhanced cytotoxic activity.
In summary, combination immunotherapy with high-
dose IL-2 and CTLA-4 blockade, compared to either
monotherapy alone, improves therapeutic responses in the
poorly immunogenic B16 murine melanoma model. This
response is dependent on recruitment of both effector
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microenvironment. Future studies will focus on the
antigen-specificity of the CD8+ T cell responses and at-
tempts to better understand how NK cells are contribut-
ing to the anti-tumor activity. In the interim, the data
support clinical development of IL-2 and CTLA-4 block-
ade as a rational combination immunotherapy for patients
with melanoma. A clinical trial testing the combination of
high-dose IL-2 and ipilimumab is planned, including an
assessment of CD8+ T and NK cell responses, and could




C57BL/6 (B6) age 6–8 weeks were purchased from The
Jackson Laboratory (Bar Harbor, ME) and housed in a
specific pathogen-free facility at Rush University Medical
Center. All melanoma cells were cultured in RPMI
supplemented with 10% heat-inactivated fetal bovine
serum (Atlanta Biologicals, Flowery Branch, GA),
2 mM L-glutamine (Mediatech, Manassas, VA), and 1%
penicillin/streptomycin (Mediatech). Animal procedures
and protocols were performed in accordance with Rush
University Medical Center Institutional Animal Care and
Use Committee guidelines.
Tumor challenge
Mice were anesthetized with isoflurane and challenged
with B16-F10 melanoma via intradermal injection with
100,000-120,000 cells in the right shaved flank (5–10
mice per group, with each experiment repeated multiple
times with similar results), as previously described [47].
Tumor area (length x width) was measured every two to
three days until death of the animal or until tumors
reached 100 mm2, when animals were sacrificed as per
institutional protocols. Primary outcomes included tumor
size and overall survival. In some experiments, tumors,
spleens, and tumor-draining inguinal lymph nodes were
obtained.
Flow cytometry and staining
Cell staining data were collected with the Canto II flow
cytometer (BD, Franklin Lakes, NJ) and analyzed with
FlowJo software (Tree Star, Ashland, OR). Gating on
live, singlet, non-debris lymphocytes was performed
using LIVE/DEAD staining, forward scatter area (FSC-A)
versus side scatter area (SSC-A), forward scatter width
(FSC-W) versus side scatter width (SSC-W), FSC-A versus
forward scatter height (FSC-H), and SSC-A versus side
scatter height (SSC-H) plots, as previously described
[48]. All non-melanoma antibodies were purchased
from eBiosciences (San Diego, CA). Intratumoral lym-
phocytes were delineated through in vivo retroorbitalinjection of anti-CD45 (FITC) three minutes prior to
tumor resection to label leukocytes restricted to the
vasculature, as previously described [49]. MHC Class I
staining was performed by gating on Melan-A-positive
cells (antibody purchased from Santa Cruz [Dallas, TX]
followed by staining for surface expression of H-2Kb. For
immunofluorescence microscopy staining tissues were
treated and images were acquired with an automated
Leica DM5500B microscope, as described previously [50].
Treatments and antibody depletions
Mice were treated with 100 μg CTLA-4 antibody block-
ade (9H10) from BioXcell (West Lebanon, NH) adminis-
tered by intraperitoneal (i.p.) injection on days 3, 6, and
9 post tumor challenge or with 100 μg of the appropriate
IgG clones (BioXcell). Recombinant human IL-2 (100,000
units resuspended in PBS delivered by i.p. injection; Pro-
metheus Laboratories, Inc., San Diego, CA) or PBS con-
trol was administered every 12 hours on days 4–8. CD8+
T cells, NK cells, CD4+ T cells, and B cells were depleted
with 250 μg of anti-CD8 (53–6.72), anti-NK1.1(PK136),
anti-CD4 (GK1.5), and anti-CD19 (1D3) purchased from
BioXcell, respectively, on days 2, 3, 6, and 9. Similarly,
250 μg of IgG (appropriate clones; BioXcell) were injected
as a control.
Statistical analysis
Student’s t test (two-tailed) and logrank test were used
for comparisons of data and survival curves, respectively,
using GraphPad Prism software (v4.0, GraphPad Software,
Inc., La Jolla, CA). A p value of less than 0.05 was consid-
ered to denote statistically significant comparisons.
Additional file
Additional file 1: Figure S1. B16 melanoma cells express high level of
MHC class I. Flow cytometric histogram of H-2kb expression on Melan-A+
cells from a tumor dissected on day 14 from a B6 mouse. Blue = isotype
staining, Red = H-2kb staining. Numbers listed correspond to MFI (mean
flourescence intensity).
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